Company Filing History:
Years Active: 2015
Title: Jerome Gabillet: Innovator in Prostaglandin Receptor Modulation
Introduction
Jerome Gabillet is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate prostaglandin receptors. His work is essential for advancing treatments for various prostaglandin-mediated diseases and disorders.
Latest Patents
Gabillet holds a patent for "7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators." This invention relates to specific chemical compounds that can be utilized in pharmaceutical compositions aimed at treating conditions influenced by prostaglandin activity. The patent outlines the formula and potential applications of these derivatives, emphasizing their role in therapeutic interventions.
Career Highlights
Jerome Gabillet is associated with Actelion Pharmaceuticals Ltd., a company known for its innovative approaches in the pharmaceutical industry. His work at Actelion has allowed him to focus on research and development in the area of receptor modulation, contributing to the advancement of medical treatments.
Collaborations
Gabillet has collaborated with notable colleagues, including Hamed Aissaoui and Christoph Boss. These partnerships have fostered a collaborative environment that enhances the research and development process within the pharmaceutical sector.
Conclusion
Jerome Gabillet's contributions to the field of prostaglandin receptor modulation highlight his innovative spirit and dedication to improving healthcare. His patent and work at Actelion Pharmaceuticals Ltd. underscore the importance of research in developing effective treatments for complex medical conditions.